Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KARTZINEL, R.
Right arrow Articles by CALNE, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KARTZINEL, R.
Right arrow Articles by CALNE, D. B.
NEUROLOGY 1976;26:741
© 1976 American Academy of Neurology

Studies with bromocriptine

III. Concomitant administration of caffeine to patients with idiopathic parkinsonism

RONALD KARTZINEL, M.D., Ph.D., IRA SHOULSON, M.D. and DONALD B. CALNE, M.D.

From the Laboratory of Neuropharmacology, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health (Drs. Kartzinel and Calne), and the Department of Neurology, University of Rochester School of Medicine, Rochester, NY (Dr. Shoulson).

Caffeine was administered to six patients with idiopathic parkinsonism in an attempt to potentiate the therapeutic response of bromocriptine, a dopamine (DA) receptor agonist, by inhibition of phosphodiesterase. In a double-blind study at doses of 1,000 mg daily, caffeine failed to enhance the antiparkinsonian action of bromocriptine (40 mg daily) given concomitantly. Although effective in potentiating the action of levodopa and other agonists in animal models of parkinsonism, caffeine is inactive in parkinsonism in man.

Requests for reprints should be addressed to Bldg. 10, Room 6D20, NIH, 9000 Rockville Pike, Bethesda, MD 20014.

Received for publication November 17, 1975.




This article has been cited by other articles:


Home page
 NeurologyHome page
D. Deleu, P. Jacob, P. Chand, S. Sarre, and A. Colwell
Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Neurology, September 12, 2006; 67(5): 897 - 899.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. A. Schwarzschild, J.-F. Chen, and A. Ascherio
Caffeinated clues and the promise of adenosine A2A antagonists in PD
Neurology, April 23, 2002; 58(8): 1154 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. W. Ross, R. D. Abbott, H. Petrovitch, D. M. Morens, A. Grandinetti, K.-H. Tung, C. M. Tanner, K. H. Masaki, P. L. Blanchette, J. D. Curb, et al.
Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease
JAMA, May 24, 2000; 283(20): 2674 - 2679.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
P. W. CURATOLO and D. ROBERTSON
The Health Consequences of Caffeine
Ann Intern Med, May 1, 1983; 98(5_Part_1): 641 - 653.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
D. B. CALNE, J. KEBABIAN, E. SILBERGELD, and E. EVARTS
Advances in the Neuropharmacology of Parkinsonism
Ann Intern Med, February 1, 1979; 90(2): 219 - 229.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.